menu
    • menu
    [{"orgOrder":0,"company":"China Pharma Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"China Pharma Holdings","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"China Pharma Holdings \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"China Pharma Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Miravo Healthcare \/ Orion Corporation"},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Nuvo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvo Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Nuvo Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | University of Chicago | University of Oklahoma","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"Cyclooxygenase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Health \/ Gansu Provincial Maternal and Child Health Care Hospital | University of Chicago | University of Oklahoma","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Gansu Provincial Maternal and Child Health Care Hospital | University of Chicago | University of Oklahoma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"McLean Hospital","sponsor":"US Department of Defense | Endeavor Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"McLean Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McLean Hospital \/ US Department of Defense | Endeavor Health","highestDevelopmentStatusID":"11","companyTruncated":"McLean Hospital \/ US Department of Defense | Endeavor Health"}]

    Find Clinical Drug Pipeline Developments & Deals for Naprosin

    Menu

    Naprosin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strides Pharma Science

                            India
                            CPhI WW Frankfurt
                            Booth # 9.1F6 & 9.1G41
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules

                            Details : USFDA approved generic version of naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.

                            Product Name : Naproxen Sodium-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 18, 2022

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy’s Announces the Re-Launch of Over-The-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equ...

                            Details : Dr. Reddy’s OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal antiinflammatory drug (NSAID) for use as a pain reliever and fever reducer. It temporarily relieves minor aches and pains.

                            Product Name : Naproxen Sodium-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 08, 2021

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Granules India Limited

                            India
                            CPhI WW Frankfurt
                            Booth #H9.1A48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Naproxen Sodium,Diphenhydramine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Granules India Receives FDA Approval for Naproxen Sodium/Diphenhydramine Tablets

                            Details : Generic of Naproxen Sodium and Diphenhydramine HCl Tablets are approved for relief of occasional sleeplessness associated with minor aches and pains and to help you fall asleep and stay asleep.

                            Product Name : Aleve-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 25, 2020

                            Lead Product(s) : Naproxen Sodium,Diphenhydramine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fa...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2010

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fe...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2010

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting Condition

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 20, 2010

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 20, 2010

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Endeavor Health

                            Country arrow
                            EPSC
                            Not Confirmed

                            Endeavor Health

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | University of Chicago | University of Oklahoma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 06, 2025

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Gansu Provincial Maternal and Child Health Care Hospital | University of Chicago | University of Oklahoma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nuvo Pharmaceuticals

                            Canada arrow
                            EPSC
                            Not Confirmed

                            Nuvo Pharmaceuticals

                            Canada arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Orion Corporation

                            Deal Size : $0.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets

                            Details : The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U....

                            Product Name : Suvexx

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Orion Corporation

                            Deal Size : $0.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            McLean Hospital

                            Country arrow
                            EPSC
                            Not Confirmed

                            McLean Hospital

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : US Department of Defense | Endeavor Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenor...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 12, 2023

                            Lead Product(s) : Naproxen Sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : US Department of Defense | Endeavor Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth